Paradigm’s Post

Paradigm is building a new model for #clinicaltrials, from the ground up, using technology to scale access. Recently, we worked with OpenAI to evaluate GPT-4 to reduce the administrative burden of screening patients for clinical trials. Our team achieved amazing results, exceeding accuracy of industry best practice while dramatically decreasing the time to read, extract, and interpret medical record data. By incorporating LLMs into Paradigm’s platform, we can screen every patient faster, more accurately, and at a dramatically lower cost, helping create equitable access for any patient, anywhere. We are excited that OpenAI shared our results here: https://lnkd.in/eE5MYUzw

We’re welcoming Kelly Haenlein to Paradigm today, where she’s taking on the newly created role of VP, Commercial Business. Paradigm’s mission is to create equitable access to clinical trials for any patient, anywhere and Kelly’s experience is perfectly matched to support that effort. In her previous role, she saw first-hand how the logistics of the clinical trial ecosystem and lack of access for so many patients can slow development of promising new therapeutics. We couldn’t be happier to have Kelly join us at Paradigm and we’re excited for her contributions.

At Paradigm, we're creating a new patient-centric model for clinical trials. When more patients have the option to participate, we can achieve better care and help bring new treatments to market faster. Today we’re announcing a new collaboration with Bristol Myers Squibb: to build a new end-to-end model for clinical trials, starting in oncology. Our two organizations share a commitment to bring access to clinical trials to underserved populations and reduce the burden of trials on patients and providers – which will speed both recruitment and results. #BristolMyersSquibb #BMS Read more in our press release here --> https://lnkd.in/g4kDd8zC

At Paradigm, we're creating a new patient-centric model for clinical trials. When more patients have the option to participate, we can achieve better care and help bring new treatments to market faster. Today we’re announcing a new collaboration with Bristol Myers Squibb: to build a new end-to-end model for clinical trials, starting in oncology. Our two organizations share a commitment to bring access to clinical trials to underserved populations and reduce the burden of trials on patients and providers – which will speed both recruitment and results.  Read more in our press release here --->https://lnkd.in/g4kDd8zC